CAMBRIDGE, England, July 8 /PRNewswire/ -- Funxional Therapeutics Ltd (Funxional) has announced today the successful completion of the first Phase I study with FX125L, an orally available small molecule which belongs to a new therapeutic class named Broad Spectrum Chemokine Inhibitors (BSCIs).
The Phase I, single ascending dose study was conducted in the United States. FX125L was well tolerated at all doses studied and no serious adverse events or subject withdrawals were observed. The pharmacokinetics of FX125L was linear over the wide dose range studied and consistent with once-daily oral dosing for patients.
"We are extremely pleased with the outcome of this initial clinical study with FX125L," said Konstantinos Efthymiopoulos, CEO of Funxional Therapeutics. "The results in humans are consistent with the preclinical data, suggesting that FX125L has a very wide safety margin, and confirmed the excellent drug-like profile of FX125L."
About Funxional Therapeutics Ltd.
Funxional Therapeutics is a privately held, clinical stage pharmaceutical
company based in Cambridge (UK) which focuses on novel anti-inflammatory
therapies. FXT is managed by a very experienced team and is financed by Index
Ventures and Novo A/S, while its shareholders also include Ipsen and
BSCIs are anti-inflammatory compounds with an entirely novel mechanism of action that involves the selective interaction with a well-characterized receptor, resulting in a potent inhibition of inflammatory cell migration. The compounds are anticipated to have broad applicability in inflammatory diseases.
BSCIs are one of the three proprietary technology platforms in FXT's
portfolio all of which originated in the
For enquiries regarding this press release, please contact Konstantinos Efthymiopoulos, CEO of Funxional Therapeutics, at +44-1223-451095.
|SOURCE Funxional Therapeutics Limited|
Copyright©2009 PR Newswire.
All rights reserved